Erratum: Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: Implications for heterogeneous accumulation of MIBG (European Journal of Nuclear Medicine and Molecular Imaging DOI: 10.1007/s00259-004-1694-7);Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: Implications for heterogeneous accumulation of MIBG

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 4, 2005, Pages 438-442

  Kiyono, Yasushi ^a   Kajiyama, Satomi ^a   Fujiwara, Hiromi ^a   Kanegawa, Naoki ^a   Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; MIBG; Norepinephrine transporter; Polyol pathway; Sympathetic nervous system

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ALDOSE REDUCTASE INHIBITOR; GLUCOSE; IODINE 123; NORADRENALIN TRANSPORTER; POLYOL; STREPTOZOCIN;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; GLUCONEOGENESIS; HEART DENERVATION; MALE; MEDICAL ASSESSMENT; NONHUMAN; NORADRENALIN RELEASE; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; SPECIES COMPARISON; STREPTOZOCIN DIABETES; SYMPATHETIC FUNCTION;

EID: 17844364260     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1865-1     Document Type: Erratum

References (31)

1. Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med 2000;27:1-6.
2. Lanza GA. Abnormal cardiac nerve function in syndrome X. Herz 1999;24:97-106.
3. Merlet P, Valette H, Dubois-Rande JL, Mardon K, Pouillart F, Bourachot ML, et al. Iodine 123-labeled metaiodobenzylguanidine imaging in heart disease. J Nucl Cardiol 1994;1:S79-85.
4. Hattori N, Tamaki N, Hayashi T, Masuda I, Kudoh T, Tateno M, et al. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med 1996;37:1985-90.
5. 123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes 1995;44:543-9.
6. Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 1995;25:610-8.
7. Schnell O, Kirsch CM, Stemplinger J, Haslbeck M, Standl E. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Diabetologia 1995;38:1345-52.
8. Yagihashi S, Yamagishi SI, Wada Ri R, Baba M, Hohman TC, Yabe-Nishimura C, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001;124:2448-58.
9. Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997;40:271-81.
10. Greene DA, Sima AA, Stevens MJ, Feldman EL, Killen PD, Henry DN, et al. Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. Diabetes Metab Rev 1993;9:189-217.
11. Kiyono Y, Iida Y, Kawashima H, Tamaki N, Nishimura H, Saji H. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: implications for heterogeneous cardiac accumulation of MIBG in diabetes. Eur J Nucl Med 2001;28:894-9.
12. Kiyono Y, Iida Y, Kawashima H, Ogawa M, Tamaki N, Nishimura H, et al. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging 2002;29:999-1005.
13. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999;53:580-91.
14. Malone JI, Knox G, Benford S, Tedesco TA. Red cell sorbitol: an indicator of diabetic control. Diabetes 1980;29:861-4.
15. 18 F]fluoro-2-deoxy-D-glucose (FDG) in mammary tumors of antiestrogen-treated rats. Nucl Med Biol 1995;22:483-9.
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the folin phenol reagent. J Biol Chem 1951;193:265-75.
17. Finegold D, Lattimer SA, Nolle S, Bernstein M, Greene DA. Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy. Diabetes 1983;32:988-92.
18. Mayhew JA, Gillon KR, Hawthorne JN. Free and lipid inositol, sorbitol and sugars in sciatic nerve obtained post-mortem from diabetic patients and control subjects. Diabetologia 1983;24:13-15.
19. Greene DA, Lattimer-Greene S, Sima AA. Pathogenesis of diabetic neuropathy: role of altered phosphoinositide metabolism. Crit Rev Neurobiol 1989;5:143-219.
20. Zhu X, Eichberg J. 1,2-Diacylglycerol content and its arachidonyl-containing molecular species are reduced in sciatic nerve from streptozotocin-induced diabetic rats. J Neurochem 1990;55:1087-90.
21. Sima AA, Brismar T. Reversible diabetic nerve dysfunction: structural correlates to electrophysiological abnormalities. Ann Neurol 1985;18:21-29.
22. Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med 1995;12:566-79.
23. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 1997;46:292-300.
24. Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci 1993;16:73-93.
25. Addicks K, Boy C, Rosen P. Sympathetic autonomic neuropathy in the heart of the spontaneous diabetic BB rat. Ann Anat 1993;175:253-7.
26. Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992;15:1902-25.
27. Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB. Diabetic neuropathies. Diabetes Care 1992;15:1926-75.
28. Cameron NE, Cotter MA. Effects of protein kinase Cβ inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev 2002;18:315-23.
29. Apparsundaram S, Galli A, DeFelice LJ, Hartzell HC, Blakely RD. Acute regulation of norepinephrine transport. I. Protein kinase C-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells. J Pharmacol Exp Ther 1998;287:733-43.
30. Apparsundaram S, Schroeter S, Giovanetti E, Blakely RD. Acute regulation of norepinephrine transport. II. PKC-modulated surface expression of human norepinephrine transporter proteins. J Pharmacol Exp Ther 1998;287:744-51.
31. Amara SG, Sonders MS, Zahniser NR, Povlock SL, Daniels GM. Molecular physiology and regulation of catecholamine transporters. Adv Pharmacol 1998;42:164-8.